ERBB2 and neoplasm: They conjugated Herceptide with ICG to yielded ICG–Herceptide (8), enabling NIR-II fluorescence imaging of HER2-positive tumors with a peak tumor-to-normal tissue (T/N) ratio of 7.3 and high-contrast intraoperative guidance in SKOV3 subcutaneous xenografts (Figure 14a–c).